NCT03438708View on ClinicalTrials.gov

Prior Axitinib as a Determinant of Outcome of Renal Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

March 4, 2026

Study Completion Date

March 4, 2026

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Axitinib Oral Tablet [Inlyta]

Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)

Trial Locations (2)

44195

Cleveland Clinic, Cleveland

92093

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

lead

University of California, San Diego

OTHER

NCT03438708 - Prior Axitinib as a Determinant of Outcome of Renal Surgery | Biotech Hunter | Biotech Hunter